XML 15 R4.htm IDEA: XBRL DOCUMENT v3.23.3
Consolidated Statements of Operations and Other Comprehensive Income (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenue        
Total Revenue $ 990,199 $ 721,905 $ 21,070,983 $ 3,600,482
Operating Expenses        
Cost of Sales 581,059 813,369 13,008,833 2,478,596
General and Administrative 2,486,044 1,979,548 7,119,288 6,500,701
Total Operating Expenses 3,067,103 2,792,917 20,128,121 8,979,297
(Loss) Income from Operations (2,076,904) (2,071,012) 942,862 (5,378,815)
Other Income (Expense)        
Interest Income 97,996 (319,768) 229,662 49,271
Foreign Exchange Transaction Gain 198,817 132,092 561,345 2,617,896
Unrealized (Loss) Gain on Securities Investment (193,991) (3,328,592) 6,349,738 (4,559,240)
Unrealized (Loss) Gain on Securities Investment - Related Party (10,548,684) (7,678,241) 560,467 (17,213,983)
Realized Loss on Securities Investment (602,624) (145,122) (11,291,166) (6,500,573)
Loss on Investment on Security by Equity Method (4,573,445) (171,385) (4,621,833) (387,435)
Loss on Consolidation of Alset Capital Acquisition (21,657,036)
Finance Costs 887 (450,000)
Other Income 717,951 346,591 1,808,489 897,129
Total Other Expense, Net (14,903,980) (11,163,538) (28,060,334) (25,546,935)
Net Loss Before Income Taxes (16,980,884) (13,234,550) (27,117,472) (30,925,750)
Income Tax (Expense) Benefit (45,124) 153,159 (45,124) (68,955)
Net Loss (17,026,008) (13,081,391) (27,162,596) (30,994,705)
Net Loss Attributable to Non-Controlling Interest (1,014,423) (1,369,265) (1,485,275) (3,827,934)
Net Loss Attributable to Common Stockholders (16,011,585) (11,712,126) (25,677,321) (27,166,771)
Comprehensive Loss Attributable to Common Stockholders        
Net Loss (16,011,585) (11,827,662) (25,677,321) (27,033,190)
Unrealized Income on Securities Investment 42,642 35,110
Foreign Currency Translation Adjustment (1,583,130) 370,778 (2,495,914) (3,131,356)
Total Comprehensive Loss Attributable to Common Stockholders (17,594,715) (11,414,242) (28,173,235) (30,129,436)
Comprehensive Loss Attributable to Non-controlling Interests        
Net Loss (1,014,423) (1,253,729) (1,485,275) (3,961,515)
Unrealized Income on Securities Investment 7,273 5,091
Foreign Currency Translation Adjustment (269,568) 63,233 (444,726) (598,368)
Total Comprehensive Loss Attributable to Non-controlling Interests $ (1,283,991) $ (1,183,223) $ (1,929,999) $ (4,554,792)
Earnings Per Share, Basic $ (1.73) $ (1.58) $ (2.86) $ (4.38)
Earnings per share, diluted $ (1.73) $ (1.58) $ (2.86) $ (4.38)
Weighted average number of shares outstanding, basic 9,235,119 7,425,359 [1] 8,976,634 6,206,145
Weighted average number of shares outstanding, diluted 9,235,119 7,425,359 [1] 8,976,634 6,206,145
Rental [Member]        
Revenue        
Total Revenue $ 705,334 $ 569,791 $ 2,030,112 $ 1,206,273
Property [Member]        
Revenue        
Total Revenue 6,300 18,197,250 1,288,434
Biohealth [Member]        
Revenue        
Total Revenue 22,154 12,786 771,847
Digital Transformation Technology Related Party [Member]        
Revenue        
Total Revenue 20 6,365 28,094 14,066
Other [Member]        
Revenue        
Total Revenue $ 278,545 $ 123,595 $ 802,741 $ 319,862
[1] The numbers of weighted average outstanding common stock - basic and diluted were adjusted retrospectively to reflect 20-for-1 reverse stock split on December 28, 2022